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ABSTRACT
Positron emission tomography (PET) is a modern functional imaging method with a proven value in diagnosing, 
staging, evaluating responses to anticancer therapy and detecting relapses in numerous neoplasms. The utility, 
sensitivity and specificity of PET has increased by its use in combination with computed tomography (CT) or 
magnetic resonance in the form of fusion PET-CT or PET-MR and the introduction of new radiotracers. This paper, 
based on scientific evidence by a multidisciplinary group of authors, presents the utility and clinical recommenda-
tions for the application of PET-CT in oncology.
PET-CT is particularly useful for:
— appropriate diagnosis and initial staging of patients with head and neck, lung, pancreatic and esophageal 
 cancers, as well as lymphomas, advanced melanomas and tumors of unknown primary site;
— detection of relapses in patients with colorectal, thyroid, ovarian, head and neck, and breast cancers, as well 
 as lymphomas;
— monitoring of response to treatment in patients with testicular and lung cancers, lymphomas and some types 
 of sarcomas.
PET-MR is particulary useful in pediatrics.
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Introduction
Positron emission tomography (PET) is a modern, 
functional imaging method used to evaluate many bio-
logical processes. The introduction of hybrid techniques 
such as a combination of PET with computed tomog-
raphy (CT) — PET-CT imaging and with the magnetic 
resonance imaging (MRI) — PET-MRI imaging has 
increased the applicability and sensitivity of PET. The 
simultaneous application of CT or MRI and PET with 
the subsequent fusion of both images allows for the 
correction of the phenomenon of the absorption of the 
radiation emitted by the radioisotope combined with 
a radiotracer and the precise positioning of the site of 
abnormal radiotracer accumulation. Another factor 
influencing the importance of PET imaging is the intro-
duction of novel radiotracers, allowing one to evaluate 
a range of phenotypic changes characteristic for dif-
ferent neoplastic processes. 18F-phosphatydyloclucose 
(18F-FDG) is still a basic radiotracer in PET imaging. 
PET imaging with the use of this radiotracer allows 
the evaluation of glucose metabolic processes, as well 
as those responsible for the Warburg phenomenon. 
An increase in 18F-FDG intake is observed not only in 
malignant neoplasms but also in many inflammatory 
changes (e.g. tuberculosis, ulcers, fungal infections, sar-
coidosis). Despite the limitation mentioned above, this 
method has a confirmed clinical value in establishing the 
diagnosis, in the initial cancer staging, in the assessment 
of the response to anticancer therapy and in the relapse 
detection in the course of many cancers.
However, the introduction of the PET-MRI method 
has not changed the indications for performing PET-CT 
imaging. PET-MRI should be considered mostly in 
children, especially when repeated PET imaging will 
be necessary to control treatment results. PET-MTI 
imaging permits an important reduction of absorbed 
radiation dose and consequently decreases the risk of 
secondary neoplasms induced by ionizing radiation. 
PET-MRI has also been proven to be more effective in 
diagnosing central nervous system (CNS) neoplasms, 
breast cancer, head and neck and pelvic neoplasms.
The aim of this paper is to analyse the utility and to 
define clinical recommendations to use PET-CT imag-
ing in oncology. The authors have considered and pres-
ent both in descriptive form and in the tables (Table 1) 
current, detailed clinical indications for using PET-CT 
imaging. The list of indications that should be reimbursed 
from public payment sources has also been proposed. 
The recommendations have been worked out based on 
evidence-based medicine principles (EBM). Three sets of 
indications are specified, namely those clinically unequivo-
cally confirmed and absolutely useful in clinical practice 
(category A), probable and potentially useful (category 
B) and individually accessed indications (category C).
In the majority of cases, the recommendations are 
based on the use of fusion PET-CT with 18F-FDG while 
some — marked separately — refer to the use of other 
radiotracers. 
The authors of this paper are specialists in different 
fields of medicine (included: clinical oncologists, radio-
therapists, surgeons and nuclear medicine specialists).
Lung cancer
Lung cancer is one of the main indications for the 
use of PET-CT imaging in oncology. PET-CT imaging 
is applied to diagnose and to access the stage of the dis-
ease prior and post anticancer treatment. The majority 
of clinical trials testing PET-CT applicability refer to 
the non-small cell lung cancer (NSCLC). There is an 
increasing clinical evidence for the utility of PET-CT 
also in the diagnostic process of small cell lung cancer 
(SCLC). Present data prove the cost effectiveness of 
PET-CT imaging in lung cancer. 
However, PET-CT imaging is not recommended as 
a screening tool for the early detection of lung cancer. 
PET-CT imaging with 18F-FDG is not recom-
mended in NSCLC patients with previously detected 
metastasis. In the neuroendocrine neoplasms the aim 
of PET-CT imaging is to assess the biological malig-
nancy of the tumour/tumours (the increased uptake 
18F-FDG within the tumour indicates more aggressive 
disease and helps to choose the appropriate treat-
ment method).
A negative result of the PET-CT of the mediastinal 
lymph nodes imaging proves limited disease. A posi-
tive result of PET-CT in mediastinal lymph nodes may 
be related to an inflammatory process and demands 
a further invasive diagnostics (ultrasound controlled 
trans-bronchial or trans-oesophageal biopsy, mediasti-
noscopy or thoracoscopy).
Initial diagnostics and pre-treatment staging
The pre-treatment indications for PET-CT diag-
nostic include: 
 — staging in patients with the diagnosis of NSCLC who 
are candidates for radical surgery or radiotherapy;
 — characterization of an suspected pulmonary nodules 
of diameter exceeding 5 mm (nodules of diameter 
below 5 mm may be an indication for PET-CT imag-
ing only when recommended by a multidisciplinary 
team with the participation of a nuclear medicine 
specialist); 
 — radiotherapy planning in selected NSCLC patients 
(e.g. extensive atelectasis of the lung) who are 
candidates for radical radio-chemotherapy or ra-
diotherapy;
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 — initial staging in a selected group of patients with 
limited SCLC being candidates for radio-chemo-
therapy. 
Post-treatment follow-up
Post-treatment PET-CT imaging is indicated in 
patients only if CT indicates the possibility of relapse 
(to differentiate between treatment side-effects and 
neoplasm relapse). 
Mesothelioma
PET-CT imaging is a clinically useful method in 
the initial diagnosis of patients with suspicion of me-
sothelioma.
The indications include:
 — selection of the most suitable site for a the effective 
biopsy in patients with suspicion of mesothelioma 
(this concerns patients with pleural thickening; 
PET-CT imaging is not useful in those patients who 
present only pleural effusion or who underwent 
pleurodesis); 
 — exclusion of neoplastic sites beyond the thorax in 
patients being candidates for combined treatment 
including surgery (pleurectomy/decortication/pleu-
ro-pneumonectomy). 
PET-CT imaging is not indicated during monitoring 
after the anticancer treatment in patients with meso-
thelioma.
Thymus neoplasms
PET-CT imaging with the use of 18F-FDG is a valu-
able method in the diagnostics of thymus cancer. The 
value of PET-CT in remaining thymus neoplasms has 
not been proven. Due to the persistent risk of thymus 
cancer, the PET-CT imaging is recommended before 
the surgical treatment of the thymus tumour.
PET-CT imaging has no value in monitoring patients 
post-thymus neoplasm treatment. 
Lymphoma
Precise initial disease staging is crucial for select-
ing an optimal treatment strategy in lymphoma pa-
tients. PET-CT imaging is currently recommended for 
patients with diagnosed lymphoma that is potentially 
curable and 18F-FDG avid, which applies mostly to 
Hodgkin lymphoma (HL), diffused large B cell lym-
phoma (DLBCL) and follicular lymphoma (FL). The 
utility of PET-CT imaging depends on histological type, 
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location and size of pathological changes (the sensitivity 
and specificity of the test decreases with a pathological 
site diameter below 10 mm) and in evaluation of the 
extra-nodal changes (e.g. eye socket, skin, spleen, stom-
ach or intestines). 
Initial diagnostics and pre-treatment staging
PET-CT imaging with the use of 18F-FDG, compared 
to another imaging methods, is characterized by the 
highest sensitivity and specificity in diagnosing patho-
logical changes, except for changes in the CNS (MRI 
imaging as the highest value in the diagnostics of focal 
changes in the CNS). Therefore CT imaging should not 
be performed before PET-CT.
PET-CT imaging is recommended in the initial stag-
ing of early and advanced stages of HL and DLBCL. 
PET-CT imaging is also useful in cases of diagnosis of 
the FL or mantle cell lymphoma (MCL). The result of 
PET-CT imaging with the use of 18F-FDG modifies 
the primary staging in about 25–30% of patients with 
HL and/or DLBCL and in about 60% of patients with 
the early stages of FL, which in consequence leads to 
a treatment plan modification in almost 30% of pa-
tients. PET-CT imaging allows for the more accurate 
measurement of the neoplastic lymph nodes, differentia-
tion of the lymph nodes from intestinal loops or to detect 
the compression or thrombosis of the large mediastinal 
vessels. PET-CT is also a method used to detect bone 
marrow involvement. In patients with HL performing 
PET-CT imaging, regardless of its result, permits one 
to avoid bone marrow trepanobiopsy. In patients with 
DLBCL positive bone marrow involvement PET-CT 
imaging result permits to avoid trepanobiopsy, but in 
case of negative PET-CT result performing trepano-
biopsy is obligatory (especially when the bone marrow 
infiltration may influence the treatment schedule). The 
interpretation of the images should be performed visu-
ally and with the use of a five degree rating scale (the 
Deauville system). 
The initial staging of the lymphomas with differenti-
ated accumulation of the radiotracer should be based 
on the CT scans with the use of an intravenous contrast. 
In cases of negative 18F-FDG PET-CT images of the 
lymphoma sites, the initial staging should be evaluated 
based on the CT scans obtained by PET-CT testing 
and the efficacy of the treatment based on the CT 
scans. PET-CT imaging has a limited use in cutaneous 
lymphomas, extra nodular marginal zone lymphomas 
(MZL) and small B cell lymphomas (SLL). 
Treatment response evaluation 
If the initial staging has been assessed by a PET-CT 
imaging result it is recommended to perform an early 
PET-CT in order to evaluate the response to treatment 
(so-called interim PET-CT) and another one at the end 
of treatment. An early PET-CT should be performed 
after the second chemotherapy cycle (directly before the 
next cycle, so that the time between the former chemo-
therapy administration and the PET-CT imaging was 
the longest possible). The aim of the interim PET-CT 
imaging is an early evaluation of the treatment efficacy. 
According to the current evidence, modification of the 
treatment method based on the interim PET-CT imag-
ing result is acceptable only when the result unequivo-
cally indicates the disease progression. In other cases, 
modification of the primary treatment plan is acceptable 
only as part of the controlled clinical trials. The interim 
PET-CT imaging must be evaluated both qualitatively 
and quantitatively. 
PET-CT imaging at the treatment completion should 
be performed after 6–8 weeks after the last chemo-
therapy administration and 12 weeks post radiotherapy. 
Complete metabolic remission is equivalent with a com-
plete response to treatment even if CT scans reveal re-
sidual masses. If PET-CT imaging detects metabolically 
active disease — and any second line treatment can be 
considered — it is recommended to perform a residual 
mass biopsy in order to obtain pathologic confirmation 
of the neoplasm before treatment administration. In 
patients receiving combined treatment, the PET-CT 
imaging should be performed 2–3 weeks after the last 
chemotherapy cycle in order to avoid any delay in ra-
diotherapy onset. 
The results of currently published studies show 
that as a negative result of the early PET-CT imaging 
does not guarantee the achievement of the complete 
remission, one cannot terminate or limit the treatment 
without risking treatment failure. Likewise, a positive 
result does not currently ensure primary resistance of 
the disease demanding treatment intensification.
It is particularly difficult to interpret the post-treat-
ment PET-CT images of foci/sites of a moderately in-
creased radiotracer 18F-FDG uptake (minimal residual 
uptake — MRU) which some authors would consider 
a risk factor for disease relapse.
Post-treatment follow-up 
It is not recommended to perform PET-CT imaging 
in patients without any clinical symptoms and who have 
achieved complete remission after treatment. In cases 
of an ambiguous result, it is recommended to repeat 
the PET-CT not earlier than after four weeks. If the 
result is still uncertain one should consider performing 
a biopsy or, in cases of further morphologic regression, 
to continue observation. 
PET-CT imaging is indicated to assess an extent 
of relapse.
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Colorectal cancer 
Although PET-CT imaging has no use in the initial 
diagnostics of colorectal cancer, it is a valuable method to 
evaluate the metastases to the other organs (especially to 
the liver) and in the diagnostics of the disease’s relapse. 
Initial diagnostics and pre-treatment staging
It is not recommended to use PET-CT imaging for 
the early detection and early diagnosis of colorectal 
cancer. The only exception is for patients with a high 
risk of disseminated disease (especially rectal cancer) 
being a contraindication for surgical treatment.
The detailed indications for the use of PET-CT im-
aging in the initial diagnostics of colorectal cancer are:
 — liver metastases detection in patients being candi-
dates for surgery;
 — the detection of the dissemination beyond the liver 
as a part of the pre-operative diagnostics in the 
patients being potential candidates for recession of 
the liver metastases. 
Post-treatment staging
PET-CT imaging is useful in the patients being can-
didates for local treatment of residual changes (resec-
tion, thermo-ablation, chemo-embolization). 
The indications for PET-CT imaging in a post-treat-
ment follow-up are: 
 — relapse detection (especially in cases of the elevated 
CEA level);
 — differentiation between relapse and treatment in-
duced changes (e.g. post radiation changes);
 — differentiation between malignant and benign 
changes (e.g. in the lymph nodes).
Oesophageal cancer 
PET-CT imaging constitutes a supplementary 
method of staging oesophageal cancer and detecting 
distant metastases (evaluation prior to the treatment 
and in cases of local reoccurrence).
The PET-CT imaging is less precise than endoscopic 
ultrasonography in evaluating the loco-regional disease. 
The value of PET-CT imaging in the treatment ef-
ficacy evaluation has not been proven.
Gastric cancer 
In advanced gastric cancer, PET-CT imaging with 
the use of 18F-fluorothymidine (FLT) is useful in the 
pre-operative staging.
Hepatocellular cancer 
In a case of suspected or diagnosed hepatocellular 
cancer, PET-CT imaging should be performed with 
the use of a carbon 11C isotope-labelled acetate. The 
method is useful in the initial staging prior to the making 
of therapeutic decisions. PET-CT imaging with the use 
of 11C traced acetate is also recommended to exclude 
potential distant metastases. 
Pancreatic cancer 
PET-CT imaging is useful in the initial differential 
diagnostics of suspicious changes in the pancreas and in 
the staging of pancreatic cancer at the different treat-
ment stages.
There is no clinical evidence for the usefulness of 
PET-CT imaging in the evaluating of the treatment ef-
ficacy of pancreatic neoplasms or during post-therapy 
follow-up.
Liver metastases
PET-CT imaging is used in the differential diagnos-
tics of the focal liver lesions when the neoplasm cannot 
be excluded by any other imaging method. 
Breast cancer 
PET-CT imaging in breast cancer is indicated in 
disease staging and in relapse detection.
Initial diagnostics and pre-treatment staging
Limited sensitivity in detecting primary neoplastic 
lesions of diameter less than 10 mm and lymph node 
axillary metastases, as well as relatively high risk of false 
positive results, does not allow to recommend PET-CT 
imaging in the initial diagnostics of breast cancer. In 
contrast, PET-CT imaging should be considered in 
patients with locally advanced disease and unequivocal 
results of the standard imaging methods. 
Post-treatment staging
Although PET-CT imaging may be helpful for 
the evaluation of response to initial chemotherapy 
(especially in cases when clinical and mammographic 
evaluation is difficult), performing the initial PET-CT 
imaging prior to the onset of treatment is mandatory. 
The clinical value of the above-mentioned indication 
has not yet been confirmed in the prospective trials.
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Post-treatment follow-up
The PET-CT imaging is useful in detecting cancer 
relapse in patients receiving radical treatment when the 
results of other tests are unequivocal and the PET-CT 
imaging result may contribute to changing the treat-
ment method. 
Uro-genital tract cancer 
Initial diagnostics and pre-treatment staging
PET-CT imaging is useful in patients diagnosed 
with locally advanced cervical cancer before planning 
radical combined treatment (radio-chemotherapy, 
radiotherapy).
Although PET-CT imaging has no proved clinical 
value in the initial diagnostics of endometrial cancer and 
ovarian neoplasms, it is highly useful in disease staging. 
The PET-CT imaging has no use in the primary 
diagnostics of testicular neoplasms. In contrast it is 
highly useful in disease staging (with exception of ma-
ture teratomas). 
PET-CT imaging with the use of choline, fluorine 
(18F), carbon (11C) and prostate specific membrane anti-
gen (PSMA)-labelled acetate is a useful test in prostate 
cancer staging. One should also consider performing 
a PET-CT test in the initial diagnostics of prostate can-
cer when the results of the repeated prostate biopsies 
are negative and, simultaneously, the prostate specific 
antigen level (PSA) is rising, or when one suspects the 
presence of metastases in the lymph nodes or bones in 
patients who are candidates for radical treatment. 
PET-CT has no use in the initial diagnostics of the 
urinary bladder. The value of PET-CT in the initial 
diagnostics of renal cancer is limited.
Post-treatment staging
Although PET-CT imaging is useful to evaluate the 
efficacy of chemotherapy in patients with seminoma 
(also in the detection of the residual changes), it is man-
datory to perform an initial PET-CT prior to the onset 
of treatment. PET-CT imaging cannot differentiate the 
character of the residual changes in a non-seminoma.
Post-treatment follow-up
PET-CT imaging is useful in detecting a relapse of 
the ovarian carcinoma (especially in cases of the elevated 
CA-125 levels) and in patients with potentially resect-
able metastases. There are no indications to perform 
a PET-CT imaging in the patients with ovarian cancer 
without any suspicion of a relapse. 
PET-CT imaging is useful for detecting the reccur-
rence of cervical cancer and of endometrial cancer (es-
pecially in patients with potentially metastatic disease). 
PET-CT imaging is not recommended in the patients 
with cervical and endometrial neoplasms when there is 
no suspicion of a relapse. 
PET-CT imaging can be used in cases of the sus-
picion of the local spread or distant metastases of the 
urinal bladder cancer in patients treated radically and 
when other imaging techniques have failed to distinguish 
the character of the changes.
PET-CT imaging with the use of choline and fluorine 
(18F), carbon (11C)-labelled acetate and gallium (68Ga)-
labelled PSMA is useful in patients with a suspicion of 
prostate cancer relapse.
PET-CT imaging has no use in post-treatment moni-
toring of patients with uro-genital neoplasms. 
Melanoma and skin neoplasms
The recommendations for use of the PET-CT imag-
ing in patients with skin melanoma without clinical signs 
of regional lymph node involvement (stage: I, II and 
IIIa/N1a and N2a) are limited. 
The PET-CT imaging cannot substitute a sentinel 
lymph node biopsy and is not useful in staging the disease 
in patients with unresectable metastases or in evaluating 
the response to systemic treatment. PET-CT imaging is 
not recommended for post-treatment observation.
PET-CT imaging with the use of 18F-FDG is char-
acterized by a high accuracy in diagnosing Merkle cell 
carcinoma. In contrast, there are no recommendations 
for PET-CT in patients with basocellular cancer at any 
stage of the disease. 
Initial diagnostics and pre-treatment staging
PET-CT imaging is useful in qualifying for surgery 
patients with melanoma in the II clinical stage (IIb/IIIc) 
with clinical symptoms of the metastases to the lymph 
modes — in 30% of patients, PET-CT imaging detects 
distant extra-nodal metastases which results in changing 
the treatment method. The early detection of distant 
metastases is actually important due to lack of any ef-
fective systemic treatment in the IV stage of the disease. 
A second — but rarely used — indication for per-
forming PET-CT imaging is the initial staging in patients 
with potentially resectable distant organ metastases 
(stage IV). In the former group of patients, the result 
of the PET-CT imaging may lead to the substitution 
of surgery with systemic treatment or to a more exten-
sive resection.
A third indication is to evaluate disease stage in 
patients with melanoma with diagnosed potentially 
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resectable metastases (e.g. the lymph nodes) without 
a defined primary disease site. 
Sarcomas
PET-CT imaging is especially useful in gastro-
intestinal stromal tumours (GIST) and in small-cell 
sarcomas (mainly Ewing sarcoma). In patients with 
GIST, PET-CT is the most sensitive method of moni-
toring the response to tyrosine kinase inhibitor treat-
ment and of detecting the progression of the disease. 
PET-CT imaging differentiates, earlier than CT, the 
cases of disease sensitive to treatment from those 
which are resistant (the response can be evaluated 
after 1–2 weeks and after 2–6 months, respectively). 
In the majority of cases, an adequate evaluation of 
response and progression of the disease can be made 
by a careful interpretation of CT scans with the use 
of the Choi criteria to evaluate changes in size and 
density of the neoplastic sites.
In some individual cases, the PET-CT can be used to 
differentiate the primary sarcomas from benign changes 
in the bones and soft tissues (e.g. in von Recklinghau-
sen’s disease). 
PET-CT imaging is also used to evaluate the re-
sponse to systemic treatment in some types of sarcomas 
(an efficacy evaluation after 1–3 chemotherapy cycles 
compared to the initial PET-CT imaging result). 
Head and neck cancer
The value of the PET-CT imaging in the initial 
diagnostics and in the evaluation of the response to 
the treatment in the patients with the epithelial head 
and neck neoplasms is becoming systematically greater.
Initial diagnostics and pre-treatment staging
PET-CT imaging is a diagnostic method of choice 
for the diagnosis of lymph node metastases from an 
unknown primary site and enables in many cases the 
localization of the primary site of neoplasm in the head 
and neck region. However, PET-CT imaging cannot 
substitute a precise endoscopy of the upper respiratory 
tracts and of the laryngeal part of the throat with a biopsy 
of the clinically suspicious cites. 
PET-CT should be also considered in selected pa-
tients with the diagnosis of locally advanced cancer in 
order to get a reliable evaluation of the lymph nodes 
metastases and to assess the extension of the infiltration 
in the primary site (this is especially important in poorly 
differentiated neoplasms with submucosal infiltrations). 
PET-CT imaging has an advantage over other imaging 
methods, especially in the evaluation of the regional 
advancement of the disease since it detects the metas-
tases to the regular lymph nodes (the sensitivity and 
the specificity to detect the metastases — respectively 
— 82–87% and 94–100%). 
PET-CT imaging is useful in radiotherapy plan-
ning (mostly in more locally or regionally advanced 
neoplasms) since it permits precise definition of target 
volume relative to the normal tissues. 
Post-treatment staging
PET-CT imaging is useful in detecting residual 
changes after treatment and local and regional re-
lapses. However, one must consider the possibility of 
false positive results (inflammatory changes — espe-
cially after radiotherapy) and false negative (especially 
residual changes in the lymph nodes). It is obligatory to 
confirm the neoplastic character of the residual changes 
or relapse, based on the histopathological evaluation of 
the excision biopsy prior to qualifying any patient for sal-
vage surgery. PET-CT imaging should not be performed 
earlier than after three months post radiotherapy or 
chemo-radiotherapy, due to the above-mentioned risk 
of false positive results, which is especially high in the 
early period after treatment. 
Recently presented results justify the use of PET-CT 
imaging in locally advanced head and neck neoplasms 
after completing radiotherapy or radio-chemotherapy, 
as it may allow one to avoid performing a lymphadenec-
tomy in nearly 80% of patients. 
Neoplasms of the central nervous 
system 
The aminoacid radiotracers — 11C labelled methio-
nine, 18F labelled tyrosine, 18F labelled dihydroxyphe-
nylalanine (DOPA) — play an important role in central 
nervous system imaging. These radiotracers show a low 
uptake in the normal brain tissues and in benign changes 
(fibrosis, necrosis, oedema). PET-CT imaging is recom-
mended in the differential diagnostics of neoplastic and 
non-neoplastic changes. The sensitivity of this test in the 
diagnostics of primary brain tumours reaches 78–94% 
while its specificity reaches 93–100%. PET-CT imaging 
may be used in the intraoperative navigating technique. 
The results of surgery using this method suggest the 
possibility of radicalizing the operation and prolonging 
survival in this group of patients compared to those 
operated on based only an MRI image. 
PET-CT imaging may be indicated to perform the 
non-invasive grading of primary CNS tumours, to de-
fine the site of a stereotactic biopsy and in cases of the 
suspicion of the neoplasm’s relapse. 
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Defining the biopsy site and tumour grading is based 
on the localization of the change in the PET-CT imaging 
and on the kinetics of the 18FET uptake in the neoplastic 
tumour. In high grade tumours, according to the World 
Health Organization (WHO) classification, positive kinet-
ics of the radiotracer uptake is observed. This method is 
used to evaluate tumours placed in the eloquent regions.
The vast majority of primary CNS neoplasms are 
characterised by isolated local growth and the risk of 
dissemination into the lymphatic system or the dis-
tant metastases is extremely low. Performing a whole 
body PET-CT in disease staging is not applicable. The 
only exceptions are low-differentiated, small-cell and 
embryonic neoplasms, occurring mostly in children 
and youths (e.g. medulloblastoma, low-differentiated 
neuroectodermal neoplasms, germ cell tumours). In 
this group of patients, one should consider performing 
a PET-CT imaging with the use of fluorine labelled 
tyrosine (18F — FET) or of carbon-labelled methionine 
(11C — MET). There are no evidence-based data for the 
role of PET-CT imaging in the differential diagnostics 
of the histological types of brain tumours. 
PET-CT imaging with the use of the 18F-FDG should 
be performed in patients with suspicion of a metastatic 
site in the brain of an unknown primary site. 
It is indicated to perform PET-CT imaging with the 
use of the following: the 18F — FET, 18F — DOPA or 
11C — MET in differentiating between a resistant or 
recurrent and active neoplasm and a post-radiotherapy 
necrosis or the so-called “pseudo-progression” of the 
tumour. PET-CT imaging combined with the MRI 
spectroscopy are the methods of choice in the localiza-
tion of the sites of increased cellular proliferation and 
higher metabolic activity. For this reason, the test should 
be performed before a planned stereotactic biopsy of 
the tumour in patients with suspected CNS neoplasm 
or of disease relapse in order to exclude the presence 
of active sites or regions of higher histological grading.
Performing PET-CT imaging with the use of the 
methionine tyrosine or DOPA after the neurosurgical 
operation is helpful in the residual tumour mass evalua-
tion and in radiotherapy planning. PET-CT imaging with 
the use of methionine or fluoride-tyrosine is valuable in 
radiotherapy planning in patients with paragangliomas 
or meningiomas. 
Endocrine system neoplasms
Each type of the endocrine system neoplasm has its 
own characteristics which can be used in PET-CT imag-
ing. Currently, there is an access in Poland — apart from 
18F-FDG — to gallium (68Ga)-labelled peptide radio-
tracers. These are very useful in diagnostics and in the 
monitoring of the clinical course of highly differentiated 
neuroendocrine neoplasms. There is a similar role for 
PET-CT using 18FDOPA applied in the monitoring of 
malignant pheochromocytoma tumours and of medul-
lary thyroid cancer. One should expect the introduction 
of another radiotracers, which will enable the specific 
differential diagnostic of neuroendocrine system neo-
plasms: metomidate (in the diagnostics of the adrenal 
cancer), iodine (124I) (useful in dosimetry — a crucial 
procedure prior to planned radioiodine administration 
to treat thyroid cancer).
PET-CT imaging with the use of 18F-FDG is not rec-
ommended in diagnostics, staging, the treatment efficacy 
assessment or the post-treatment follow-up — in the most 
frequent — a highly-differentiated thyroid cancer which 
uptakes 131I. However, this method plays a key role in the 
detection and localization of the metastases in patients 
with an increased serum level of thyreoglobulin and a neg-
ative scintigraphy result with the use of 131I. In patients 
with dissemination of a thyroid neoplasm with a positive 
iodine uptake test, the result of the 18F-FDG-PET has 
a prognostic value: the increased uptake of the radiotracer 
suggests a higher resistance to the 131I treatment.
In medullar thyroid cancer, PET-CT imaging is a rea-
sonable method in order to localize a relapse in a case 
when the calcitonin level exceeds 500 pg/ml, (one should 
consider performing also a DOPA-PET, which is not 
reimbursed in Poland despite an EBM-confirmed rec-
ommendation).
In adrenal cortex carcinoma, PET-CT imaging is 
a complementary test in disease staging.
In some neuroendocrine neoplasms it is necessary 
to perform PET imaging with the use of 68Ga and 
18F-FDG-labelled somatostatin derivates. The first of 
these radiotracers enables the evaluation of the ex-
pression of the somatostatin receptor system while the 
second defines the biological malignancy of the primary 
site and of the metastases. The results of both tests are 
the basis for choosing the optimal treatment method and 
predicting the clinical course of the disease. 
Neoplasms with an unknown primary site
PET-CT imaging is useful in the diagnostics of se-
lected patients with metastases with an unknown primary 
site of a neoplasm. The value of the PET-CT depends 
on the location of lesion (high — e.g. metastases to 
the cervical lymph nodes, low e.g. — metastases to the 
subdiaphragmatic lymph nodes).
Bone metastases 
PET-CT (especially with the use of the 18F-NaF 
tracer) is characterised by a high sensitivity in the 
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evaluation of bone metastases. This test is recom-
mended in patients with an ambiguous result of a bone 
scintigraphy with the use of 99Tc-MDP. PET-CT 
with 18F-FDG has a slightly lower sensitivity but 
a higher specificity.
Proposed criteria for qualification to 
PET-CT imaging and list of oncological 
recommendations which should be 
reimbursed from public sources:
 — a solitary lung tumour larger than 5 mm in diameter 
— in order to differentiate between its benign and 
the malignant character if the diagnosis cannot be 
made by any other accessible method;
 — non-small cell lung cancer — in order to stage the 
disease prior to a planned resection or radical ra-
diotherapy and in order to evaluate regional disease 
extension and to exclude distant metastases (apart 
from formerly detected distant metastases);
 — small-cell lung cancer in the stage of limited disease 
— prior to radical combined treatment;
 — mesothelioma — prior to radical combined treat-
ment with the use of surgery;
 — mediastinal tumour — prior to combined radical 
treatment with the use of surgery; 
 — Hodgkin lymphoma and non-Hodgkin lymphomas 
— in order to perform initial staging, evaluation of 
treatment efficacy or for early relapse detection;
 — colon cancer — in order to perform pre-operative 
clinical staging or for early relapse detection after the 
radical treatment (when the results of other imaging 
exams are ambiguous);
 — oesophageal cancer — in order to access to staging 
prior to radical treatment and in early relapse detec-
tion post radical treatment (when the results of other 
imaging exams are ambiguous);
 — gastric cancer — in preoperative disease staging in 
cases of unequivocal results of other exams;
 — pancreatic cancer — in initial disease staging prior to 
radical treatment (when the results of other imaging 
exams are ambiguous);
 — pathological changes in the pancreas and in the liver 
— evaluation of changes suspected of a neoplastic 
character when a diagnosis cannot be made using 
other methods; 
 — breast cancer — in the initial diagnostics in order to 
exclude distant metastases (when the results of other 
exams are unequivocal);
 — breast cancer — during the follow-up post radical 
treatment in cases where there is a suspicion of re-
lapse when the results of other imaging exams are 
ambiguous and the PET-CT result may change the 
treatment method;
 — ovarian cancer — in order to define the disease stage 
in the patients with potentially resectable metastases 
and for early detection of the relapse post radical 
treatment (in cases of increased Ca125 levels or 
unequivocal results of other exams);
 — cervical and endometrial cancer — in order to ac-
cess the disease stage prior to radical treatment 
and for early detection of a relapse post radical 
therapy (when the results of the imaging exams 
are unequivocal);
 — testis neoplasms (except from mature teratomas) 
— in disease staging and in the evaluation of treat-
ment efficacy (including residual tumour and relapse 
detection) if evaluation cannot be made by the 
other methods;
 — urinary bladder cancer — in disease staging in the 
patient with potentially resectable metastases and 
in order to detect the relapse of the disease after 
radical treatment when the imaging exams results 
are unequivocal;
 — suspicion of prostate cancer in cases of elevated PSA 
levels and a negative result of a repeated transrectal 
prostate biopsy — in order to localize the neoplasm 
the exam should be carried out with the use of ac-
etate, choline or PSMA);
 — prostate cancer — prior to radical treatment but only 
when the metastases and the results of other exams 
are unequivocal (PTE-CT imaging with the use of 
the acetate, choline or PSMA);
 — prostate cancer — in relapse (metastases) detec-
tion post radical treatment (an exam with the use 
of PSMA, choline or acetate), when the diagnosis 
cannot be made by other exams);
 — renal cancer — in relapse (metastases) detection 
post radical treatment (an exam with the use of 
acetate), when the diagnosis cannot be made by 
other exams);
 — melanomas — in patients with clinically overt me-
tastases to regional lymph nodes and potentially 
resectable metastases in the distant organs or with 
potentially resectable metastasis with an unknown 
primary site;
 — Merkel cell cancer — in initial disease staging prior 
to the treatment and in relapse or dissemination di-
agnostics;
 — sarcomas — in order to differentiate benign and 
malignant changes and in staging prior to treat-
ment and as the reference exam in chemotherapy 
efficacy evaluation and during chemotherapy (after 
1–3 chemotherapy cycles in order to compare with 
the initial PET-CT exam) and for the early detec-
tion of relapse;
 — gastrointestinal stromal tumours (GIST) — in order 
to monitor the molecular response to the target 
treatment and to detect relapse of the disease; 
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 — head and neck neoplasms — in order to detect 
the relapse of the disease early and to evaluate 
loco-regional staging when the results of other exams 
are ambiguous;
 — central nervous system — in order to evaluate the 
areas of higher malignancy, to detect relapse early 
and to define the biopsy site (imaging examination 
indicated with the use of fluorine-labelled tyrosine, 
methionine or DOPA);
 — mature thyroid cancer — in order to differentiate 
and evaluate the localization of a relapse in the cases 
of elevated thyroglobulin levels if this site cannot be 
diagnosed by other exams (it is obligatory to perform 
a 131I scintigraphy earlier);
 — neuroendocrine tumours — in the initial disease 
staging; PET-CT with the use of radiotracers evaluat-
ing the expression of the receptors and with 18F-FDG 
in order to define the character of the metastatic 
changes and the grade of the malignancy prior to 
the planned treatment with radioisotope-labelled 
somatostatin analogues;
 — metastases of an unknown primary site — in order 
to localize the primary site when it cannot be defined 
by other accessible exams;
 — suspicion of metastases to the bones — when the 
result of a scintigraphy is unequivocal;
 — planning of radical radiotherapy — in order to lo-
calize the foci of living neoplastic cells, of hypoxia 
or of the proliferation of a tumour when such an 
evaluation cannot be done by the other methods. 
PET-MRI imaging is recommended in diagnostics 
of the liver, of the pelvic organs and of the brain only if 
the aforementioned criteria are met. 
PET-MRI is recommended in children up to 18 years 
of age only if the aforementioned recommendations for 
PET-CT imaging are met. 
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